Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2001

View Archived Issues

Sonus updates recent achievements with three development products

Bristol-Myers Squibb highlights significant developments during 2000

Geron regains rights to telomerase inhibitors from Pharmacia; forms new division

Xenogen establishes two new license agreements

Highly potent, short peptide attenuates head trauma-associated mortality and brain damage

PBOX-6 shows potential for bypassing apoptotic suppressor Bcr-Abl in CML

Oxford BioMedica and AHP jointly develop novel antibody cancer therapy

Production, development of recombinant mammastatin planned by Biotherapies

IDEC-131 commences phase II trial for psoriasis

Increased ACR20 response rate reported with 5G1.1

BioChem Pharma reviews progress during the year

Enrollment begins in phase III trial of Leuprogel 4-month for prostate cancer

Zofenopril reaches market for two cardiovascular indications

Starlix, the first in a new class of agents for type 2 diabetes, recommended for E.U. approval

Cel-Sci/NCI CRADA renewed and expanded

New heterocyclic chemopreventive agents described in U.S. patent

Japanese scientists reveal new antiasthmatic series

Substituted benzodioxan, benzofuran or benzopyran derivatives useful for GI disorders

Novel anticoagulants synthesized and tested at Aventis

Inhibitors of JNK, compositions and methods of use described by Vertex team

Positive modulation of AMPA receptors achieved with new CoCensys compounds

Merck reports synthesis, use of new peptidomimetic protein prenyltransferase inhibitors

New antihistaminic/antiallergic agents designed by Almirall Prodesfarma

U.S. introduction of first-in-class antifungal agent for life-threatening infections imminent

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026